Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Changes in Neuronal Oscillations Accompany the Loss of Hippocampal LTP that Occurs in an Animal Model of Psychosis.

Kalweit AN, Amanpour-Gharaei B, Colitti-Klausnitzer J, Manahan-Vaughan D.

Front Behav Neurosci. 2017 Mar 8;11:36. doi: 10.3389/fnbeh.2017.00036. eCollection 2017.

2.

Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency - molecular profiling and functional rescue.

Addis L, Virdee JK, Vidler LR, Collier DA, Pal DK, Ursu D.

Sci Rep. 2017 Dec;7(1):66. doi: 10.1038/s41598-017-00115-w. Epub 2017 Feb 27.

3.

A de novo loss-of-function GRIN2A mutation associated with childhood focal epilepsy and acquired epileptic aphasia.

Gao K, Tankovic A, Zhang Y, Kusumoto H, Zhang J, Chen W, XiangWei W, Shaulsky GH, Hu C, Traynelis SF, Yuan H, Jiang Y.

PLoS One. 2017 Feb 9;12(2):e0170818. doi: 10.1371/journal.pone.0170818. eCollection 2017.

4.

GluN2D-Containing N-methyl-d-Aspartate Receptors Mediate Synaptic Transmission in Hippocampal Interneurons and Regulate Interneuron Activity.

Perszyk RE, DiRaddo JO, Strong KL, Low CM, Ogden KK, Khatri A, Vargish GA, Pelkey KA, Tricoire L, Liotta DC, Smith Y, McBain CJ, Traynelis SF.

Mol Pharmacol. 2016 Dec;90(6):689-702. Epub 2016 Sep 13.

PMID:
27625038
5.

Synaptic and cellular changes induced by the schizophrenia susceptibility gene G72 are rescued by N-acetylcysteine treatment.

Pósfai B, Cserép C, Hegedüs P, Szabadits E, Otte DM, Zimmer A, Watanabe M, Freund TF, Nyiri G.

Transl Psychiatry. 2016 May 10;6:e807. doi: 10.1038/tp.2016.74.

6.

GluN2D N-Methyl-d-Aspartate Receptor Subunit Contribution to the Stimulation of Brain Activity and Gamma Oscillations by Ketamine: Implications for Schizophrenia.

Sapkota K, Mao Z, Synowicki P, Lieber D, Liu M, Ikezu T, Gautam V, Monaghan DT.

J Pharmacol Exp Ther. 2016 Mar;356(3):702-11. doi: 10.1124/jpet.115.230391. Epub 2015 Dec 16.

7.

NMDA Receptors Mediate Stimulus-Timing-Dependent Plasticity and Neural Synchrony in the Dorsal Cochlear Nucleus.

Stefanescu RA, Shore SE.

Front Neural Circuits. 2015 Nov 20;9:75. doi: 10.3389/fncir.2015.00075. eCollection 2015.

8.

Measurement of Bmax and Kd with the glycine transporter 1 radiotracer ¹⁸F-MK6577 using a novel multi-infusion paradigm.

Xia Y, Zheng MQ, Holden D, Lin SF, Kapinos M, Ropchan J, Gallezot JD, Huang Y, Carson RE.

J Cereb Blood Flow Metab. 2015 Dec;35(12):2001-9. doi: 10.1038/jcbfm.2015.163. Epub 2015 Jul 22.

9.

RoR2 functions as a noncanonical Wnt receptor that regulates NMDAR-mediated synaptic transmission.

Cerpa W, Latorre-Esteves E, Barria A.

Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4797-802. doi: 10.1073/pnas.1417053112. Epub 2015 Mar 30.

10.

Inhibition of parvalbumin-expressing interneurons results in complex behavioral changes.

Brown JA, Ramikie TS, Schmidt MJ, Báldi R, Garbett K, Everheart MG, Warren LE, Gellért L, Horváth S, Patel S, Mirnics K.

Mol Psychiatry. 2015 Dec;20(12):1499-507. doi: 10.1038/mp.2014.192. Epub 2015 Jan 27.

11.

Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophrenia.

Wonodi I, McMahon RP, Krishna N, Mitchell BD, Liu J, Glassman M, Hong LE, Gold JM.

Schizophr Res. 2014 Dec;160(1-3):80-7. doi: 10.1016/j.schres.2014.10.026. Epub 2014 Nov 14.

12.

Computational psychiatry.

Wang XJ, Krystal JH.

Neuron. 2014 Nov 5;84(3):638-54. doi: 10.1016/j.neuron.2014.10.018. Epub 2014 Nov 5. Review.

13.

Recent genetic findings in schizophrenia and their therapeutic relevance.

Harrison PJ.

J Psychopharmacol. 2015 Feb;29(2):85-96. doi: 10.1177/0269881114553647. Epub 2014 Oct 14. Review.

14.

1-aminocyclopropanecarboxylic acid (ACPC) produces procognitive but not antipsychotic-like effects in rats.

Popik P, Holuj M, Nikiforuk A, Kos T, Trullas R, Skolnick P.

Psychopharmacology (Berl). 2015 Mar;232(6):1025-38. doi: 10.1007/s00213-014-3738-4. Epub 2014 Sep 27.

15.

Glutamate-mediated excitotoxicity in schizophrenia: a review.

Plitman E, Nakajima S, de la Fuente-Sandoval C, Gerretsen P, Chakravarty MM, Kobylianskii J, Chung JK, Caravaggio F, Iwata Y, Remington G, Graff-Guerrero A.

Eur Neuropsychopharmacol. 2014 Oct;24(10):1591-605. doi: 10.1016/j.euroneuro.2014.07.015. Epub 2014 Aug 1. Review.

16.

Altered serine/threonine kinase activity in schizophrenia.

McGuire JL, Hammond JH, Yates SD, Chen D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE.

Brain Res. 2014 Jun 3;1568:42-54. doi: 10.1016/j.brainres.2014.04.029. Epub 2014 Apr 26.

17.

Impact of glutamate levels on neuronal response and cognitive abilities in schizophrenia.

Falkenberg LE, Westerhausen R, Craven AR, Johnsen E, Kroken RA, L Berg EM, Specht K, Hugdahl K.

Neuroimage Clin. 2014 Apr 2;4:576-84. doi: 10.1016/j.nicl.2014.03.014. eCollection 2014.

18.

Functional analysis of a de novo GRIN2A missense mutation associated with early-onset epileptic encephalopathy.

Yuan H, Hansen KB, Zhang J, Pierson TM, Markello TC, Fajardo KV, Holloman CM, Golas G, Adams DR, Boerkoel CF, Gahl WA, Traynelis SF.

Nat Commun. 2014;5:3251. doi: 10.1038/ncomms4251.

19.

Effects of nicotine on the neurophysiological and behavioral effects of ketamine in humans.

Mathalon DH, Ahn KH, Perry EB Jr, Cho HS, Roach BJ, Blais RK, Bhakta S, Ranganathan M, Ford JM, D'Souza DC.

Front Psychiatry. 2014 Jan 24;5:3. doi: 10.3389/fpsyt.2014.00003. eCollection 2014.

20.

Impaired fear memory specificity associated with deficient endocannabinoid-dependent long-term plasticity.

Lovelace JW, Vieira PA, Corches A, Mackie K, Korzus E.

Neuropsychopharmacology. 2014 Jun;39(7):1685-93. doi: 10.1038/npp.2014.15. Epub 2014 Jan 24.

Supplemental Content

Support Center